# Thomas Powles

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thomas-powles/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,515 |
| Field | Bladder and Urothelial Cancer Treatments |
| h-index | 82 |
| i10-index | 250 |
| Last Known Institution | Queen Mary University of London |
| OpenAlex ID | https://openalex.org/A5089861374 |
| ORCID iD | https://orcid.org/0000-0001-7760-4724 |
| Works | 683 |

## Researcher papers

- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma](https://scholariq.org/papers/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)

## Researcher topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Queen Mary University of London](https://scholariq.org/institutions/queen-mary-university-of-london/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.